

ALL WALES MEDICINES STRATEGY GROUP

THURSDAY, 14TH FEBRUARY 2008 COMMENCING 10.30 AM
(UNTIL 4.30 PM APPROX)
AT THE WALES MILLENIUM STADIUM

AGENDA

Enclosure

1. Welcome and introduction
2. Apologies
3. Declarations of interest
4. Chairman's report (verbal update)
5. Minutes of previous meeting
- Matters arising 1/AWMSG/0208
6. **Appraisal 1 – topotecan hydrochloride (Hycamtin[®])**
GlaxoSmithKline
Intravenous (IV) topotecan is licensed for use in patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate 2/AWMSG/0208
Appendices
7. **Appraisal 2 – topotecan hydrochloride (Hycamtin[®])**
GlaxoSmithKline
Topotecan in combination with cisplatin for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease. 3/AWMSG/0208
Appendices
8. **Appraisal 3 –tacrolimus (Advagraf[®])**
Astellas Pharma Ltd
Prophylaxis of transplant rejection in adult kidney or liver allograft recipients. Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients 4/AWMSG/0208
Appendices
9. **Appraisal 4 –epoetin delta (Dynepo[®])**
Shire Pharmaceuticals
Treatment of anaemia in patients with chronic renal failure. Dynepo[®] may be used in patients on dialysis and patients not on dialysis 5/AWMSG/0208
Appendices
10. Report on NHS Industry Forum 6/AWMSG/0208
11. Report on AWPAG
- Proposed anticoagulation audit 7/AWMSG/0208
Appendices
12. AWMSG Prescribing Strategy 8/AWMSG/0208
Appendices

13. The Risk Management of Injectable Medicines therapy 9/AWMSG/0208
14. Consultation on rare diseases 10/AWMSG/0208

Date of next AWMSG meeting: Wednesday, 16th April 2008
Venue – The Angel Hotel, Abergavenny